The Challenges and Knowledge Gaps in Malaria Therapy: A Stakeholder Approach to Improving Oral Quinine Use in the Treatment of Childhood Malaria in Ghana

Table 3

Knowledge on the availability of some antimalarial drugs.

Antimalarial drug	Strongly agree ()	Agree ()	Neutral ()	Disagree ()	Strongly disagree ()
Chloroquine	57.5	32.8	5.5	1.5	2.8
Quinine	66	25.8	5.2	1.3	1.6
Amodiaquine	59.6	30.5	6.3	1.7	1.9
Halofantrine	17	16.7	41.6	13.8	11
Primaquine	12.7	16.3	44.1	14.6	12.3
Mefloquine	11.6	17.6	43.9	2.7	12.4
Artesunate	57.1	22.5	12.6	3.1	4.8
Dihydroartemisinin	18.9	23.8	34.4	13.2	9.8
Piperaquine	12.4	24.6	36.8	14.3	11.9
Sulfadoxine & Pyrimethamine	19.5	20.9	34.6	12.7	12.3
ACTs
Artesunate + amodiaquine	69.5	22.5	4.3	1.3	2.4
Artemether + lumefantrine	61	25.5	8.2	2.4	2.9
Dihydroartemisinin + piperaquine	21.1	25.3	33.2	11.9	8.6
Artesunate + Mefloquine	10.8	21.4	40.1	16.8	10.8
Artesunate + Sulfadoxine & Pyrimethamine	12.2	22.2	39.3	15.6	10.8
Marketed Brands of ACTs
Lonart	63.8	28.5	4.5	1.1	2.1
Coartem	57.8	29.4	7	2.5	3.3
Lumether	50.9	27.5	14.3	3.3	3.9
Malar-	43.3	23.7	19.7	7	6.4
P-Alaxin	35.3	24.9	24.5	8	7.4
Danmether	31	20.5	31	9	8.6
Gen-M	34.5	15.6	25.4	9.8	14.7